CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10MG)

What Is the CJC-1295 & Hexarelin Blend and Why Buy It for Research?

Buy CJC-1295 & Hexarelin Blend in Switzerland for research into growth hormone axis signaling, synergistic GH release, and metabolic regulation. Specifically, this research formulation combines two complementary growth hormone secretagogues in a single pre-mixed lyophilized vial: CJC-1295 (Mod GRF 1-29, 5mg) and Hexarelin (5mg). This 10mg blend pairs a growth hormone-releasing hormone (GHRH) analog with a growth hormone secretagogue (GHS) to probe convergent pathways in the GH-IGF-1 axis.

CJC-1295 (without DAC, also known as Modified GRF 1-29) is a synthetic peptide analog of GHRH that activates the GHRH receptor on anterior pituitary somatotrophs, driving cAMP/PKA-mediated GH synthesis and secretion. Hexarelin is a synthetic hexapeptide growth hormone secretagogue (GHS) that engages the GHS-R1a receptor through Gq/11-coupled signaling, mobilizing intracellular calcium to trigger GH granule release. When combined, these two peptides produce synergistic GH release significantly higher than either compound alone. Furthermore, Core Peptides supplies this blend as a lyophilized powder in a 10mg format exclusively for laboratory use. Therefore, researchers seeking to source this combination for their work will find it readily available when they buy CJC-1295 & Hexarelin Blend in Switzerland.

CJC-1295 & Hexarelin Blend Research Overview: Buy CJC-1295 & Hexarelin Blend in Switzerland for GH Axis Studies

Centrally, research into the CJC-1295 and Hexarelin blend has focused on the complementary and synergistic mechanisms of its two components. The foundational observation that GHRH + GHRP produces synergistic GH release was established by Bowers et al. in human subjects, demonstrating that co-administration of GHRH and GHRP-6 produced GH peaks 2-3 fold higher than either peptide alone.

CJC-1295 (Mod GRF 1-29) functions as a GHRH analog that binds to the GHRH receptor (GHRH-R), a G-protein coupled receptor (GPCR) on pituitary somatotrophs. This binding activates a downstream signaling cascade that results in GH synthesis and release. In clinical studies, subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults. The form without DAC (Mod GRF 1-29) has a shorter half-life of approximately 30 minutes and mimics the natural, pulsatile release of GHRH.

Hexarelin is a synthetic hexapeptide belonging to the GH-releasing peptide (GHRP) family that possesses GH-releasing activity greater than that of GHRH both in animals and in man. It acts directly on specific pituitary receptors and indirectly on the hypothalamus. Hexarelin also engages the scavenger receptor CD36, which mediates many of its GH-independent cardioprotective effects including anti-atherosclerotic and anti-ischemic activity.

When combined, CJC-1295 sustains physiologic pulsatile GH secretion while Hexarelin elevates basal GH tone and suppresses hypothalamic somatostatin. The combination amplifies GH output through convergent but mechanistically independent pathways. Accordingly, researchers who buy CJC-1295 & Hexarelin Blend in Switzerland from Core Peptides can support their investigations into GH axis signaling, synergistic peptide interactions, and metabolic regulation.

How Does the CJC-1295 & Hexarelin Blend Work in Research?

Mechanistically, the CJC-1295 and Hexarelin blend operates through two complementary signaling pathways that converge on GH release from pituitary somatotrophs.

CJC-1295 (Mod GRF 1-29) Mechanism: CJC-1295 activates the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, driving cAMP/PKA-mediated GH synthesis and secretion. It functions as a stable and active hGRF1-29 analog. The form without DAC, known as Mod GRF 1-29, has a half-life of approximately 30 minutes and mimics the natural, pulsatile release of GHRH. This pulsatile pattern replicates the natural secretion of growth hormone. CJC-1295 shows a 4-fold increase in GH area under the curve over a 2-hour period compared with hGRF1-29.

Hexarelin Mechanism: Hexarelin engages the GHS-R1a receptor through Gq/11-coupled signaling, mobilizing intracellular calcium to trigger GH granule release. Three different mechanisms are postulated for Hexarelin stimulation of GH secretion in vivo: a direct action on the pituitary, though of minor relevance; an indirect action that involves release of GHRH, of relevance only in adult rats; and an additional mechanism. Hexarelin also binds the scavenger receptor CD36, which mediates many of its GH-independent cardioprotective effects including anti-atherosclerotic and anti-ischemic activity.

Synergistic Effects: The combination of a GHRH analog (CJC-1295) with a GHS (Hexarelin) produces synergistic (not merely additive) GH release. CJC-1295 sustains physiologic pulsatile GH secretion while Hexarelin elevates basal GH tone and suppresses hypothalamic somatostatin. The combination amplifies GH output through convergent but mechanistically independent pathways. Combining a GHRP (hexarelin) with a GHRH (CJC-1295) produces synergistic GH release significantly higher than either compound alone.

GH-Independent Effects: Beyond GH axis effects, Hexarelin’s CD36 binding provides direct cardiac myocyte protection, anti-inflammatory signaling, and lipid metabolism modulation that complement the anabolic and metabolic effects of elevated GH/IGF-1. Hexarelin has demonstrated anti-cachectic effects independent of GH release, preserving skeletal muscle mitochondrial function and calcium homeostasis during catabolic states.

Why Is the CJC-1295 & Hexarelin Blend Studied in Switzerland?

Primarily, researchers study this blend because it represents a well-characterized combination of two complementary GH secretagogues that enables investigation of synergistic GH release, metabolic regulation, and cardioprotective pathways. In fact, this pre-mixed blend offers a practical way to study convergent GH axis signaling without the need to source and reconstitute each compound separately.

Research has demonstrated the blend’s relevance across multiple domains. GH pulse amplitude is a key determinant of recovery-relevant downstream effects including IGF-1 elevation, protein synthesis stimulation, lipolysis, and collagen synthesis. Research in GH-deficient models demonstrates that pulsatile GH administration is more effective than continuous infusion for promoting lean body mass and reducing adiposity, supporting the value of high-amplitude pulse protocols. Hexarelin specifically has demonstrated anti-cachectic effects independent of GH release. Combined with CJC-1295’s sustained GH axis stimulation, this stack provides both GH-dependent anabolic signaling and GH-independent muscle-protective effects. Ultimately, researchers who buy CJC-1295 & Hexarelin Blend in Switzerland gain access to a comprehensive research tool for investigating GH axis signaling, metabolic regulation, and cardioprotective mechanisms.

CJC-1295 & Hexarelin Blend Research Areas in Laboratory Studies

Research Area	Focus	Key Components
GH Axis Signaling	Synergistic GH release, GHRH/GHS receptor crosstalk, pulsatile secretion	Both (complementary pathways)
Metabolic Regulation	IGF-1 elevation, lipolysis, protein synthesis, collagen synthesis	Both (GH-dependent effects)
Cardioprotection	CD36-mediated cardiac protection, anti-atherosclerotic, anti-ischemic	Hexarelin (GH-independent)
Muscle Preservation	Anti-cachectic effects, mitochondrial function, calcium homeostasis	Hexarelin (GH-independent)
Recovery and Body Composition	Lean body mass, adiposity reduction, recovery-related signaling	Both
Receptor Pharmacology	GHRH-R, GHS-R1a, CD36 binding, downstream signaling cascades	Both (distinct targets)

CJC-1295 & Hexarelin Blend Compared With Related Research Formulations

Formulation	Components	Research Focus	Key Difference
CJC-1295 + Hexarelin Blend	CJC-1295 (Mod GRF 1-29) + Hexarelin	GH axis, synergistic release, cardioprotection, metabolism	Strongest GH pulse; Hexarelin adds CD36 cardioprotection
CJC-1295 + Ipamorelin	CJC-1295 (Mod GRF 1-29) + Ipamorelin	GH release, metabolic regulation	Weaker GH pulse; minimal cortisol/prolactin spillover
CJC-1295 with DAC	CJC-1295 with Drug Affinity Complex	Sustained GH elevation, growth and metabolism	Single peptide; extended half-life (6-8 days)
Hexarelin alone	Hexarelin (GHRP)	GH release, cardioprotection	Single peptide; lacks GHRH component for synergy

Comparatively, the CJC-1295 and Hexarelin blend differs from other GHRH/GHS combinations in its potency and additional mechanisms. On the one hand, Hexarelin is the most potent GHRP, producing GH peaks of 40-80 mcg/L as monotherapy compared to 15-30 mcg/L for Ipamorelin at equivalent doses. On the other hand, combining Hexarelin with CJC-1295 produces the strongest combined GH pulse. In contrast, CJC-1295 with Ipamorelin is frequently chosen for minimal cortisol and prolactin spillover, while CJC-1295 with DAC provides sustained elevation rather than pulsatile release.

Research Applications for the CJC-1295 & Hexarelin Blend in Switzerland

Scientists have investigated this peptide blend across several research domains:

• GH Axis Signaling Research: Researchers use this blend to study synergistic GH release, GHRH/GHS receptor crosstalk, and pulsatile GH secretion dynamics.
• Metabolic Regulation Studies: The blend is employed to investigate IGF-1 elevation, lipolysis, protein synthesis, and collagen synthesis pathways.
• Cardioprotection Research: Hexarelin’s CD36-mediated cardiac protection, anti-atherosclerotic, and anti-ischemic activity are studied in cardiovascular research models.
• Muscle Preservation Studies: Investigations have explored Hexarelin’s anti-cachectic effects, mitochondrial function preservation, and calcium homeostasis in catabolic states.
• Recovery and Body Composition: Research has examined the blend’s effects on lean body mass, adiposity reduction, and recovery-related signaling pathways.
• Receptor Pharmacology: The blend serves as a tool for studying GHRH-R, GHS-R1a, and CD36 receptor binding and downstream signaling cascades.

Evidently, researchers who buy CJC-1295 & Hexarelin Blend in Switzerland gain a valuable addition to any laboratory toolkit focused on GH axis signaling, metabolic research, and cardioprotective mechanisms.

CJC-1295 & Hexarelin Blend Product Specifications

Specification	Details
Product Name	CJC-1295 & Hexarelin Blend
Alternative Names	Mod GRF 1-29 + Hexarelin, CJC-1295/Hexarelin stack, GHRH/GHS blend
Total Content	10mg
Composition	CJC-1295 (Mod GRF 1-29) 5mg + Hexarelin 5mg (1:1 ratio)
Form	Lyophilized powder
Purity	Not verified (≥98-99% HPLC purity reported by some suppliers)
CJC-1295 Sequence	Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg (29 amino acids)
Hexarelin Sequence	His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂ (6 amino acids)
Hexarelin Molecular Weight	887.1 g/mol
Research Category	Growth Hormone Peptides / Muscle & Performance
Research Use	Laboratory research use only
CoA	Available upon request (not verified)
Storage	Lyophilized powder should be stored desiccated at -20°C or below, protected from light
Solubility	Soluble in water and bacteriostatic water; reconstitute slowly

How to Evaluate CJC-1295 & Hexarelin Blend Quality for Research

When sourcing this peptide blend for laboratory research, researchers should consider several quality indicators:

• Identity Confirmation: Analytical techniques such as mass spectrometry should confirm the identity and molecular weight of each component peptide.
• Purity Assessment: High-performance liquid chromatography (HPLC) should verify purity of each peptide, with ≥98% considered standard for research-grade material.
• Batch Traceability: Lot numbers and batch information enable researchers to track specific production runs.
• Certificate of Analysis: A CoA should accompany the product, detailing analytical testing results for each component.
• Labeling Accuracy: Proper labeling should clearly indicate the product name, composition (5mg CJC-1295 + 5mg Hexarelin), total content, and storage recommendations.
• Storage Conditions: Appropriate storage at -20°C or below in desiccated, dark conditions helps maintain peptide stability.

Understanding the Certificate of Analysis

Typically, a Certificate of Analysis (CoA) accompanies research peptide blends and provides information about the specific batch’s analytical testing. For example, a CoA may include product identity confirmation for each component, purity percentages as determined by HPLC, batch or lot number for traceability, analytical methods used (e.g., mass spectrometry, HPLC), and a physical description of the product.

Nevertheless, it is important to note that a CoA does not establish safety, efficacy, therapeutic effectiveness, or suitability for human use. Instead, it serves as a quality control document that helps researchers verify the identity and purity of the peptides they are using in their laboratory investigations.

Storage and Stability of the CJC-1295 & Hexarelin Blend

Core Peptides supplies this blend as a lyophilized (freeze-dried) powder. To maintain stability and integrity:

• Store the lyophilized powder desiccated at -20°C or below for long-term storage
• Store at 4°C for short-term storage if frequent access is required
• Avoid repeated freeze-thaw cycles
• Reconstitute only immediately before use with appropriate sterile solvents (e.g., bacteriostatic water or sterile water)
• Inject solvent slowly against the inner wall of the vial rather than directly onto the powder; do not shake
• Gently roll the vial in a circular motion to dissolve
• Once reconstituted, refrigerate at 2°C to 8°C and utilize promptly
• Protect from light and moisture

Frequently Asked Questions About Buying the CJC-1295 & Hexarelin Blend in Switzerland

What is the CJC-1295 & Hexarelin Blend?

Specifically, this 10mg blend combines CJC-1295 (Mod GRF 1-29, 5mg) and Hexarelin (5mg) in a 1:1 ratio. It pairs a GHRH analog with a growth hormone secretagogue for synergistic GH release research.

What is the blend researched for?

Primarily, researchers study this blend for its synergistic GH release, metabolic regulation, IGF-1 elevation, and GH-independent cardioprotective effects. It is most often discussed for GH axis signaling, recovery research, and metabolic studies.

How does the blend work?

Mechanistically, CJC-1295 activates the GHRH receptor on pituitary somatotrophs, driving GH synthesis, while Hexarelin engages GHS-R1a, triggering GH release. The combination produces synergistic GH output through convergent but mechanistically independent pathways.

What is the composition of the blend?

The blend contains CJC-1295 (Mod GRF 1-29) 5mg and Hexarelin 5mg for a total of 10mg.

What is the amino acid sequence of CJC-1295?

CJC-1295 is a 29-amino acid peptide: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg.

What is Hexarelin?

Hexarelin is a synthetic hexapeptide growth hormone secretagogue (GHS) with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂. It is a member of the GH-releasing peptide (GHRP) family.

How does Hexarelin differ from other GHRPs?

Hexarelin is the most potent GHRP, producing higher GH peaks than Ipamorelin or GHRP-2 at equivalent doses. It also binds CD36 for GH-independent cardioprotective effects.

What evidence exists for the blend?

The synergistic effect of combining a GHRH analog with a GHS is well-established in the literature. To date, there appear to be no published laboratory experiments evaluating the specific combination of CJC-1295 and Hexarelin. Each peptide has been studied individually for its respective mechanisms.

Is the blend approved as a medicine?

No. Regulatory authorities have not approved the blend as a medicine, pharmaceutical, or therapeutic agent. It is a research tool for laboratory use only.

Is the blend intended for human use?

No. The blend is intended for laboratory research use only and is not for human consumption, injection, or therapeutic application.

Where can I buy the CJC-1295 & Hexarelin Blend in Switzerland?

You can buy the CJC-1295 & Hexarelin Blend in Switzerland from Core Peptides, a trusted research peptide supplier serving the Swiss scientific community.

How should researchers evaluate the quality of this blend?

Researchers should look for identity confirmation via mass spectrometry for each component, purity data from HPLC, batch traceability, and a Certificate of Analysis.

Related Research Compounds

Researchers interested in the CJC-1295 & Hexarelin Blend may also find the following related compounds relevant to their work:

• CJC-1295 (Mod GRF 1-29) — Individual GHRH analog researched for GH synthesis and pulsatile secretion.
• Hexarelin — Individual GHRP researched for GH release, cardioprotection, and CD36 binding.
• CJC-1295 & Ipamorelin Blend — Alternative GHRH/GHS blend with weaker GH pulse and minimal cortisol/prolactin spillover.
• Ipamorelin — A GHRP researched for GH release with minimal side effects.

Explore Growth Hormone Peptides

The CJC-1295 & Hexarelin Blend belongs to the Growth Hormone Peptides category of research compounds. Growth Hormone Peptides products are studied for their potential roles in GH axis signaling, metabolic regulation, and growth-related pathways. Generally, researchers who buy this blend in Switzerland often pair it with related compounds in this category to explore complementary pathways in GH research and metabolic studies.

Explore Muscle & Performance

Researchers studying muscle preservation, recovery, and performance-related mechanisms may also find relevant compounds in the Muscle & Performance category. The blend’s effects on GH-dependent anabolic signaling and GH-independent muscle-protective effects make it a valuable tool for investigating muscle function and recovery.

Further Research

For researchers seeking to deepen their understanding of the CJC-1295 & Hexarelin Blend and its research applications, the following areas may warrant further investigation:

• The relationship between combined GHRH/GHS activity and specific downstream signaling pathways in different cell types
• Comparative studies between the CJC-1295/Hexarelin blend and individual components in various GH axis and metabolic models
• The potential for Hexarelin’s CD36-mediated cardioprotection to complement GH-dependent anabolic effects
• Mechanistic studies on peptide stability and compatibility in blended systems
• Exploration of the blend’s effects on different tissue systems beyond musculoskeletal and metabolic models

Research Disclaimer

The CJC-1295 & Hexarelin Blend is a research peptide formulation supplied for laboratory research use only. Researchers must not use it for human consumption, injection, or any form of therapeutic application. Moreover, this product is not a medicine, pharmaceutical, or medical device. Furthermore, Swissmedic, the FDA, EMA, or any other regulatory authority have not approved it for human use. Researchers should consult Swissmedic for applicable regulations and guidance on research peptide handling in Switzerland.

Generally, the information provided on this page is for educational and scientific reference purposes only. Therefore, it does not constitute medical advice, treatment recommendations, or dosing instructions. Ultimately, researchers bear the responsibility for ensuring that their use of this product complies with all applicable laws, regulations, and institutional guidelines.

Finally, all research involving peptide blends should be conducted by qualified personnel in appropriate laboratory settings with proper safety protocols.